MedPath

LPR Fluorescence Pilot

Conditions
Laryngopharyngeal Reflux
Gastro Esophageal Reflux
Interventions
Diagnostic Test: 24-hour pH-impedance monitoring
Other: Symptom questionnaires
Other: ROME IV Diagnostic Questionnaire
Registration Number
NCT05204303
Lead Sponsor
The Functional Gut Clinic
Brief Summary

Comparing the fluorescence signatures from mouthwash samples of patients with laryngopharyngeal reflux (LPR) and healthy volunteers.

Detailed Description

The investigators aim to test if the biosensing platform Pandra, developed by Rosa Biotech, may be suitable to distinguish patients with LPR symptoms, both with and without objective evidence of gastroesophageal reflux disease (GORD), vs healthy volunteers due to their expected inflammation and cell changes in the laryngo-pharyngeal region. The investigators intend to analyse 20 samples of mouthwash solutions from each of the following groups:

A. Patients with symptoms of LPR and objective evidence of GORD B. Patients with symptoms of LPR and no objective evidence of GORD C. Healthy volunteer group

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Participant is Aged 18 or above
  • Participant has capacity to understand written English
  • Participant is not on regular prescription medicines
  • Participant has an RSI score of 0
  • Participant has a body mass index (BMI) of 18.5 - 34.9 kg/m2 (bounds included)
Exclusion Criteria
  • Participant has experienced any symptoms of LPR or GORD symptoms in the past year
  • Participant has taken any medication for GORD/LPR in the past year (e.g. proton pump inhibitors, h2 antagonists, over the counter antacids)
  • Participant has active oral disease
  • Participant has a significant medical diagnosis

Patients with symptoms of LPR

Inclusion Criteria:

  • Participant is Aged 18 or above
  • Participant has capacity to understand written English
  • Participant has an RSI score of >13
  • Participant has a body mass index (BMI) of 18.5 - 34.9 kg/m2 (bounds included
  • Participant has been referred for 24hr ambulatory pH-impedance monitoring

Exclusion Criteria:

  • Participant has active oral disease
  • Participant has other ongoing health problems that could account for their LPR symptoms.
  • Participant has NOT undergone nasoendoscopy within last 6 months OR does not have one scheduled within next 6 weeks
  • Previous antireflux surgery (e.g. fundoplication or magnetic sphincter augmentation)
  • Previous bariatric surgery (e.g. gastric bypass or sleeve gastrectomy)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with symptoms of LPR and no objective evidence of GORDSymptom questionnaires-
Patients with symptoms of LPR and objective evidence of GORDSymptom questionnaires-
Patients with symptoms of LPR and no objective evidence of GORD24-hour pH-impedance monitoring-
Patients with symptoms of LPR and no objective evidence of GORDROME IV Diagnostic Questionnaire-
Patients with symptoms of LPR and objective evidence of GORD24-hour pH-impedance monitoring-
Patients with symptoms of LPR and objective evidence of GORDROME IV Diagnostic Questionnaire-
Healthy volunteersSymptom questionnaires-
Healthy volunteersROME IV Diagnostic Questionnaire-
Primary Outcome Measures
NameTimeMethod
Determine the detection strength of differences in fingerprints between the three participant groups.10-months
Secondary Outcome Measures
NameTimeMethod
Determine the differences in fingerprints between samples within one group to assess background noise.10-months
Determine the feasibility of mouthwash on Pandra platform.10-months

Trial Locations

Locations (1)

The Functional Gut Clinic

🇬🇧

Manchester, Greater Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath